PHASE 1 STUDY OF AMG 160, A HALF-LIFE EXTENDED BITE (R) (BISPECIFIC T-CELL ENGAGER) THERAPY TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN, IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Dorff, T; Rettig, M; Machiels, JP; Lolkema, M; Autio, K; Greil, R; Rottey, S; Adra, N; Salvati, M; Poon, S; Tan, D; Jurida, G; Kouros-Mehr, H; Fizazi, K; Tran, B; Horvath, L

View this publication in the PUBMED database